<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

Hs 695T

Description

HS 695T (Melanoma CDX Model) 

The HS 695T melanoma line was derived from a metastatic melanoma lesion. It is representative of aggressive melanoma progression. HS 695T has been applied in preclinical research focused on therapy resistance. Its reproducibility makes it a reliable system for translational oncology. 

Key Features: 

  • Derived from metastatic melanoma. 
  • Represents advanced melanoma biology. 
  • Highly tumorigenic in xenografts. 
  • Suitable for resistance mechanism studies. 

Applications: 
HS 695T is used in testing novel therapeutics for metastatic melanoma. It supports drug resistance and biomarker discovery programs. Researchers employ it to investigate mechanisms of tumor progression. Its aggressive phenotype makes it valuable for late-stage melanoma studies.

Details
Skin
Ameloanotic Melanoma
Human
Female
NOG
Mutated Genes
ATM
Mutation: p.Q1825Ter
Effect: Stop-Gain
Impact: Pathogenic
*Data provided by DepMap
BRAF
Mutation: p.V600E
Effect: Missense Variant
Impact: Pathogenic & Likely Pathogenic & Not Provided
*Data provided by DepMap
NF1
Mutation: p.Q959Ter
Effect: Stop-Gain
Impact: Pathogenic
*Data provided by DepMap
TERT
Effect: Upstream Gene Variant
Impact: Pathogenic
*Data provided by DepMap
Expression Data (provided by DepMap)
Growth Curve